Mar 24, 2015 | News
NIA/NIH grant support for Phase 2a clinical testing of a new, potentially disease-modifying therapy tor Alzheimer’s disease. Read More
Jan 23, 2015 | News
T3D Therapeutics was one of only thirteen companies selected to participate in this year’s CED Life Science Conference Showcase, March 3-4, 2015. CED received over 70 applicants and the Selection Committee felt that T3D represented one of the best new companies in the...
Jun 4, 2014 | News
T3D Therapeutics announced it has been awarded a competitive $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center. The SRL Program funds research to advance development of commercially viable technologies/products. Through the SRL...
Apr 2, 2014 | News
T3D Therapeutics announced today that it had a successful Type B Pre-Investigational New Drug (“Pre-IND) meeting on April 1st with the US Food and Drug Administration’s Division of Neurology Products, for T3D-959, a novel nuclear receptor agonist for the treatment of...
Feb 28, 2014 | News
T3D Therapeutics announced that is successfully completed a Series A1/A2 Preferred Equity Offering pursuant to rule 506 regulation D of the Securities Act of 1933. New and current angel investors participated.
Oct 21, 2013 | News
T3D Therapeutics announced the addition of Dr. Suzanne de al Monte to its Advisory Board. Suzanne de la Monte, MD, MPH, is a physician scientist who directs basic and translational research in the laboratory and performs clinical service work in Neuropathology. Her...
